Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.40 |
| ▸ | PRKCG | P05129 | 3/20 | 0.40 |
| ▸ | PRKCB | P05771 | 3/20 | 0.40 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191467 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MAPTPKMHPGDHSD17B10 | |
| SCHEMBL3192805 | 0.81 | TSHR (0.51) | ALDH1A1MAPTCYP3A4CYP1A2CYP2C19 | |
| SCHEMBL3192798 | 0.81 | TSHR (0.51) | ALDH1A1MAPTCYP3A4CYP1A2CYP2C19 | |
| SCHEMBL3188136 | 0.80 | TSHR (0.41) | ALDH1A1MAPTPKMHPGDHSD17B10 | |
| SCHEMBL5922917 | 0.80 | TSHR (0.41) | ALDH1A1MAPTPKMHPGDHSD17B10 | |
| SCHEMBL6746135 | 0.80 | TSHR (0.41) | ALDH1A1MAPTPKMHPGDHSD17B10 | |
| SCHEMBL3192474 | 0.78 | TSHR (0.61) | ALDH1A1HPGDCYP3A4CYP1A2CYP2C19 | |
| SCHEMBL3197889 | 0.78 | TSHR (0.61) | ALDH1A1HPGDCYP3A4CYP1A2CYP2C19 | |
| SCHEMBL3194600 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTPKMHPGDHSD17B10 | |
| SCHEMBL5922834 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTPKMHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379249-A4 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
| EP-1379249-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002067939-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ALDH1A1 3191/4885MAPT 4124/4885PKM 1226/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ALDH1A1 3191/4885MAPT 4124/4885PKM 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.